Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA: First-line Olaparib vs CDK4/6 inhibitor plus endocrine therapy in gBRCA-mutated HR+/HER2- metastatic breast cancer
KCT0006750Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib in breast cancer (2 arms), sponsored by AstraZeneca. Started Oct 2021; status: recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0006750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006750.